Amarin Corporation (AMRN) Q3 2024 earnings summary

Executive summary

• Q3 2024 net revenue was $42.3M, down 36% year-over-year, mainly due to a 51% drop in U.S. sales from generic competition and PBM coverage loss, while European and international sales grew, supported by new launches and reimbursement wins.

• Management executed strategic priorities: U.S. market share retention (maintaining over 50% IPE share), European revenue acceleration, and ROW partnership growth, with ongoing cost optimization and a strong cash position for nine consecutive quarters.

• Organizational restructuring reduced annual operating costs by $50M, eliminating the U.S. sales force and 30% of non-sales roles.

• Board and management are evaluating all options to optimize shareholder value and maintain NASDAQ compliance.

• International expansion advanced with new approvals and launches in China, Europe, and other regions, offsetting some U.S. revenue declines.

Financial highlights

• Q3 2024 total net revenue was $42.3M, down from $66.1M in Q3 2023; U.S. product revenue declined to $30.6M from $62.4M, while European net product revenue grew to $4.3M and ROW revenue reached $6.9M.

• Gross margin dropped to 38% from 64% year-over-year, mainly due to lower U.S. net selling prices.

• GAAP net loss was $25.1M, compared to a $19.3M loss in Q3 2023; adjusted net loss (non-GAAP) was $20.4M.

• Operating expenses were reduced by $10M year-over-year due to cost optimization.

• Cash and investments totaled $305.7M as of September 30, 2024, with no debt.

Outlook and guidance

• Management expects continued net pricing pressure and revenue declines in the U.S. due to increasing rebates, generic competition, and PBM coverage changes.

• Focus remains on expanding international markets, accelerating European growth, securing reimbursement, and supporting global partners.

• Cash and investments are expected to fund operations for at least 12 months; share repurchase program authorized but not yet commenced.